EGFR and non-small cell lung carcinoma: A phase III randomized trial evaluating patritumab deruxtecan versus platinum-based chemotherapy after failure of EGFR TKI therapy is ongoing in metastatic or locally advanced EGFR-mutant NSCLC in the HERTHENA-Lung02 trial (NCT 05338970).